Filing Details
- Accession Number:
- 0001209191-15-018743
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-02-25 18:10:57
- Reporting Period:
- 2015-02-23
- Filing Date:
- 2015-02-25
- Accepted Time:
- 2015-02-25 18:10:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1281895 | Inotek Pharmaceuticals Corp | ITEK | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1291884 | Medimmune Ventures, Inc. | One Medimmune Way Gaithersburg MD 20878 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-02-23 | 1,255,123 | $0.00 | 1,444,035 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2015-02-23 | 57,204 | $0.00 | 1,501,239 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2015-02-23 | 416,667 | $6.00 | 1,917,906 | No | 4 | P | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series AA Convertible Preferred Stock | Disposition | 2015-02-23 | 4,013,692 | $0.00 | 1,255,123 | $0.00 |
| Common Stock | Convertible Promissory Notes | Disposition | 2015-02-23 | 338,551 | $0.00 | 57,204 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Consists of the following shares of Common Stock issued upon conversion of shares of Series AA Convertible Preferred Stock ("Series AA") and accrued and unpaid dividends thereon, on a 4.05783-for-1 basis, upon the closing of the Issuer's initial public offering: 1,255,123 shares held directly by MedImmune Ventures, Inc. The shares of Series AA had no expiration date.
- The outstanding principal amount and all accrued and unpaid interest under the Convertible Promissory Notes will be automatically converted upon the closing of the Issuer's initial public offering into shares of Common Stock at the initial public offering price of $6.00 per share. The Convertible Promissory Notes have no expiration date. The number of shares of Common Stock as shown in column 3 is based on a conversion of $338,551.12 of principal amount of Convertible Promissory Notes, plus accrued and unpaid interest through the assumed closing date of February 23, 2015.
- The outstanding principal amount and all accrued and unpaid interest under the Convertible Promissory Notes were automatically converted upon the closing of the Issuer's initial public offering into shares of Common Stock at the initial public offering price of $6.00 per share. The Convertible Promissory Notes had no expiration date. The number of shares of Common Stock as shown in column 4 of Table I consists of 57,204 shares held directly by MedImmune Ventures, Inc.
- Consists of the following shares purchased at the Issuer's initial public offering: 416,667 shares held directly by MedImmune Ventures, Inc.
Billionaire Hedge Funds
